Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRWV NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRWVCoreWeave$105.55+0.1%$100.73$63.80▼$187.00$47.24B7.8428.01 million shs18.36 million shsMDGLMadrigal Pharmaceuticals$527.06+1.9%$507.97$265.00▼$615.00$12.15B-1.04341,685 shs118,733 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRWVCoreWeave0.00%+1.66%-4.22%+6.23%+2.68%MDGLMadrigal Pharmaceuticals0.00%-0.95%+0.95%+17.56%+93.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRWVCoreWeave$105.55+0.1%$100.73$63.80▼$187.00$47.24B7.8428.01 million shs18.36 million shsMDGLMadrigal Pharmaceuticals$527.06+1.9%$507.97$265.00▼$615.00$12.15B-1.04341,685 shs118,733 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRWVCoreWeave0.00%+1.66%-4.22%+6.23%+2.68%MDGLMadrigal Pharmaceuticals0.00%-0.95%+0.95%+17.56%+93.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRWVCoreWeave 2.52Moderate Buy$129.6322.81% UpsideMDGLMadrigal Pharmaceuticals 2.76Moderate Buy$687.0030.35% UpsideCurrent Analyst Ratings BreakdownLatest CRWV and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026CRWVCoreWeave DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$175.00 ➝ $100.005/14/2026CRWVCoreWeave CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$155.00 ➝ $158.005/13/2026MDGLMadrigal Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$640.00 ➝ $709.005/11/2026CRWVCoreWeave BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$106.00 ➝ $120.005/11/2026CRWVCoreWeave Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$156.00 ➝ $167.005/8/2026CRWVCoreWeave Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$135.005/8/2026CRWVCoreWeave Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$85.00 ➝ $131.005/8/2026CRWVCoreWeave Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $155.005/8/2026CRWVCoreWeave Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.005/8/2026CRWVCoreWeave JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$90.00 ➝ $105.005/8/2026CRWVCoreWeave MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$105.00 ➝ $110.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRWVCoreWeave$5.13B9.21$3.75 per share28.18$10.63 per share9.93MDGLMadrigal Pharmaceuticals$958.40M12.68N/AN/A$23.57 per share22.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRWVCoreWeave-$1.17B-$3.11N/AN/AN/A-25.57%-43.07%-3.84%N/AMDGLMadrigal Pharmaceuticals-$288.28M-$12.80N/A55.60N/A-27.32%-50.15%-25.44%8/4/2026 (Estimated)Latest CRWV and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026MDGLMadrigal Pharmaceuticals-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 million2/26/2026Q4 2025CRWVCoreWeave-$0.61-$0.89-$0.28-$0.89N/A$1.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRWVCoreWeaveN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRWVCoreWeave3.680.310.31MDGLMadrigal Pharmaceuticals0.633.503.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRWVCoreWeaveN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipCRWVCoreWeaveN/AMDGLMadrigal Pharmaceuticals17.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRWVCoreWeave2,189447.57 millionN/AN/AMDGLMadrigal Pharmaceuticals9023.06 million19.00 millionOptionableCRWV and MDGL HeadlinesRecent News About These CompaniesMadrigal Pharmaceuticals, Inc. $MDGL Stock Position Trimmed by William Blair Investment Management LLCMay 24 at 6:52 AM | marketbeat.comRichard Levy Sells 5,682 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMay 23 at 7:50 AM | insidertrades.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 22, 2026 | marketbeat.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)May 21, 2026 | globenewswire.comAnalyzing Journey Medical (NASDAQ:DERM) and Madrigal Pharmaceuticals (NASDAQ:MDGL)May 21, 2026 | americanbankingnews.comMadrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskMay 20, 2026 | markets.businessinsider.comMadrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskMay 20, 2026 | globenewswire.comDavid Soergel Sells 844 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMay 19, 2026 | insidertrades.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Given New $709.00 Price Target at Truist FinancialMay 13, 2026 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for MDGL EarningsMay 12, 2026 | marketbeat.comA Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales GrowthMay 11, 2026 | finance.yahoo.comWhat is HC Wainwright's Estimate for MDGL FY2029 Earnings?May 11, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 9, 2026 | seekingalpha.comMadrigal Pharmaceuticals (MDGL) Receives a Buy from BarclaysMay 9, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Pennant Group (PNTG)May 9, 2026 | theglobeandmail.comH.C. Wainwright Remains a Buy on Madrigal Pharmaceuticals (MDGL)May 7, 2026 | theglobeandmail.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comMadrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpMay 7, 2026 | zacks.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Beats Expectations By $0.98 EPSMay 6, 2026 | marketbeat.comMadrigal Pharmaceuticals Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comMadrigal: Q1 Earnings SnapshotMay 6, 2026 | stamfordadvocate.comSNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Leading Insider Sales: April Activity Ramps in These StocksBy Thomas Hughes | May 5, 2026CRWV and MDGL Company DescriptionsCoreWeave NASDAQ:CRWV$105.55 +0.06 (+0.06%) As of 03:34 PM EasternCoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.Madrigal Pharmaceuticals NASDAQ:MDGL$527.06 +9.80 (+1.89%) As of 03:32 PM EasternMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
